Total Payments
$25,932
2024 Payments
$13.56
Companies
37
Transactions
182
Medicare Patients
1,398
Medicare Billing
$148,700
Payment Breakdown by Category
Travel$8,759 (33.8%)
Research$7,484 (28.9%)
Consulting$4,930 (19.0%)
Food & Beverage$4,651 (17.9%)
Education$108.07 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $8,759 | 18 | 33.8% |
| Unspecified | $7,484 | 16 | 28.9% |
| Consulting Fee | $4,930 | 2 | 19.0% |
| Food and Beverage | $4,651 | 137 | 17.9% |
| Education | $108.07 | 9 | 0.4% |
Payments by Type
General
$18,448
166 transactions
Research
$7,484
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma Global Development | $12,402 | 10 | $0 (2019) |
| AstraZeneca AB | $2,365 | 8 | $0 (2018) |
| AstraZeneca UK Limited | $2,354 | 9 | $0 (2017) |
| Ferring Pharmaceuticals Inc. | $2,026 | 17 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $1,522 | 9 | $0 (2020) |
| GlaxoSmithKline, LLC. | $1,255 | 12 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $1,076 | 3 | $0 (2020) |
| Astellas Pharma US Inc | $586.37 | 18 | $0 (2020) |
| Foundation Medicine, Inc. | $293.40 | 1 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $227.41 | 8 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13.56 | 1 | Endo USA, Inc. ($13.56) |
| 2023 | $14.49 | 1 | Boston Scientific Corporation ($14.49) |
| 2022 | $178.99 | 7 | Antares Pharma, Inc. ($93.78) |
| 2020 | $2,665 | 17 | Merck Sharp & Dohme Corporation ($1,437) |
| 2019 | $7,875 | 37 | Astellas Pharma Global Development ($6,122) |
| 2018 | $3,019 | 46 | AstraZeneca AB ($2,365) |
| 2017 | $12,166 | 73 | Astellas Pharma Global Development ($6,280) |
All Payment Transactions
182 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/19/2024 | Endo USA, Inc. | AVEED (Biological), XIAFLEX | Food and Beverage | In-kind items and services | $13.56 | General |
| Category: UROLOGY | ||||||
| 12/12/2023 | Boston Scientific Corporation | LithoVue (Device) | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: LithoVue_URO | ||||||
| 09/14/2022 | Endo Pharmaceuticals Inc. | XIAFLEX (Biological), AVEED, EDEX | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: UROLOGY | ||||||
| 08/08/2022 | PFIZER INC. | XTANDI (Drug), ORGOVYX, PAXLOVID | Food and Beverage | In-kind items and services | $13.61 | General |
| Category: ONCOLOGY | ||||||
| 06/16/2022 | Endo Pharmaceuticals Inc. | XIAFLEX (Biological), EDEX, AVEED | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: UROLOGY | ||||||
| 05/18/2022 | Endo Pharmaceuticals Inc. | XIAFLEX (Biological), EDEX, AVEED | Food and Beverage | In-kind items and services | $19.44 | General |
| Category: UROLOGY | ||||||
| 05/15/2022 | Antares Pharma, Inc. | NOCDURNA (Drug) | Food and Beverage | In-kind items and services | $43.78 | General |
| Category: NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS | ||||||
| 05/13/2022 | Antares Pharma, Inc. | TLANDO (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 02/15/2022 | Endo Pharmaceuticals Inc. | XIAFLEX (Biological), EDEX, AVEED | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: UROLOGY | ||||||
| 09/01/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| Category: Oncology | ||||||
| 07/29/2020 | Cook Medical LLC | Cook Medical Urology (Device) | Food and Beverage | Cash or cash equivalent | $25.51 | General |
| Category: Urology | ||||||
| 06/26/2020 | Travere Therapeutics, Inc. | (815) Thiola (Drug) | Education | In-kind items and services | $3.82 | General |
| Category: Kidney Stones | ||||||
| 02/26/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $433.00 | General |
| Category: ONCOLOGY | ||||||
| 02/26/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $62.69 | General |
| Category: ONCOLOGY | ||||||
| 02/26/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $59.98 | General |
| Category: ONCOLOGY | ||||||
| 02/26/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: ONCOLOGY | ||||||
| 02/25/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $225.00 | General |
| Category: ONCOLOGY | ||||||
| 02/25/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $144.23 | General |
| Category: ONCOLOGY | ||||||
| 02/25/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $103.09 | General |
| Category: ONCOLOGY | ||||||
| 02/24/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $373.70 | General |
| Category: ONCOLOGY | ||||||
| 02/05/2020 | TOLMAR Pharmaceuticals, Inc. | ELIGARD (Drug) | Food and Beverage | In-kind items and services | $12.11 | General |
| Category: Prostate Cancer | ||||||
| 02/03/2020 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $21.97 | General |
| Category: Oncology | ||||||
| 01/31/2020 | Astellas Pharma US Inc | XTANDI (Drug) | Food and Beverage | In-kind items and services | $15.24 | General |
| Category: ONCOLOGY | ||||||
| 01/28/2020 | Cook Medical LLC | Cook Medical Urology (Device) | Food and Beverage | Cash or cash equivalent | $23.35 | General |
| Category: Urology | ||||||
| 01/22/2020 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $11.05 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure | Astellas Pharma Global Development | $4,121 | 1 |
| A PHASE 3 STUDY TO COMPARE THE EFFICACY AND SAFETY OF GEPOTIDACIN WITH | GlaxoSmithKline, LLC. | $1,255 | 12 |
| A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide Who Are at Potential Increased Risk of Seizure | Astellas Pharma Global Development | $812.00 | 1 |
| A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure | Astellas Pharma Global Development | $810.00 | 1 |
| A Phase 2, Open-label, Single-arm, Efficacy and Safety Study of Enzalutamide (MDV3100) in Patients With Hormone-naive Prostate Cancer | Astellas Pharma Global Development | $486.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 3 | 64 | 107 | $39,365 | $13,222 |
| 2020 | 20 | 1,334 | 25,683 | $221,968 | $135,479 |
Total Patients
1,398
Total Services
25,790
Medicare Billing
$148,700
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 37 | 63 | $22,702 | $7,565 | 33.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 13 | 21 | $11,409 | $3,929 | 34.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 14 | 23 | $5,254 | $1,727 | 32.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 374 | 490 | $70,866 | $50,100 | 70.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 431 | 575 | $57,452 | $31,384 | 54.6% |
| 52000 | Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | Office | 2020 | 64 | 78 | $19,590 | $13,708 | 70.0% |
| 52356 | Crushing of stone in urinary duct (ureter) with stent using an endoscope | Facility | 2020 | 18 | 18 | $12,875 | $8,558 | 66.5% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 46 | 46 | $10,571 | $6,809 | 64.4% |
| 74176 | Ct scan of abdomen and pelvis | Office | 2020 | 57 | 63 | $15,266 | $5,889 | 38.6% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Office | 2020 | 17 | 17 | $6,490 | $3,906 | 60.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 40 | 42 | $3,950 | $2,858 | 72.3% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 37 | 162 | $3,392 | $2,081 | 61.3% |
| 55700 | Biopsy of prostate gland | Facility | 2020 | 15 | 15 | $5,389 | $1,938 | 36.0% |
| 51700 | Bladder irrigation and/or instillation | Office | 2020 | 12 | 23 | $2,645 | $1,660 | 62.8% |
| 52332 | Insertion of stent in urinary duct (ureter) using an endoscope | Facility | 2020 | 12 | 13 | $3,123 | $1,567 | 50.2% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 17 | 17 | $2,382 | $1,159 | 48.6% |
| 74018 | X-ray of abdomen, 1 view | Office | 2020 | 42 | 71 | $2,558 | $1,050 | 41.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2020 | 11 | 15 | $1,244 | $992.76 | 79.8% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2020 | 73 | 97 | $1,874 | $839.05 | 44.8% |
| 76942 | Ultrasonic guidance imaging supervision and interpretation for insertion of needle | Facility | 2020 | 15 | 15 | $1,392 | $502.05 | 36.1% |
| J1071 | Injection, testosterone cypionate, 1 mg | Office | 2020 | 14 | 23,851 | $624.48 | $260.36 | 41.7% |
| 93005 | Routine electrocardiogram (ekg) with tracing using at least 12 leads | Office | 2020 | 27 | 27 | $257.04 | $198.08 | 77.1% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2020 | 12 | 48 | $26.88 | $20.97 | 78.0% |
About William Clark
William Clark is a Urology healthcare provider based in Anchorage, Alaska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1073567079.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, William Clark has received a total of $25,932 in payments from pharmaceutical and medical device companies, with $13.56 received in 2024. These payments were reported across 182 transactions from 37 companies. The most common payment nature is "Travel and Lodging" ($8,759).
As a Medicare-enrolled provider, Clark has provided services to 1,398 Medicare beneficiaries, totaling 25,790 services with total Medicare billing of $148,700. Data is available for 2 years (2020–2022), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Other Specialties Urology
- Location Anchorage, AK
- Active Since 05/22/2006
- Last Updated 11/11/2021
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1073567079
Products in Payments
- XTANDI (Drug) $6,381
- LYNPARZA (Drug) $4,719
- Xtandi (Drug) $4,256
- Enzalutamide (Drug) $2,159
- DEGARELIX (Drug) $1,632
- KEYTRUDA (Biological) $1,522
- OPDIVO (Biological) $1,076
- FOUNDATIONONE (Device) $293.40
- MYRBETRIQ (Drug) $149.36
- PROVENGE (Drug) $138.91
- FIRMAGON (Drug) $133.70
- Erleada (Drug) $133.50
- Myrbetriq (Drug) $131.52
- Xofigo (Drug) $94.04
- TALZENNA (Drug) $89.99
- ADCETRIS (Biological) $89.08
- CONTINENCE CARE (Device) $88.06
- XIAFLEX (Biological) $87.97
- NOCDURNA (Drug) $75.12
- IMFINZI (Drug) $71.25
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Anchorage
Joshua Logan, Md, MD
Urology — Payments: $16,012
Urology $16,012
Elysia Spencer, Md, MD
Urology — Payments: $8,140
Urology $8,140
Andre' Godet, M.d, M.D
Urology — Payments: $5,732
Urology $5,732
Bryan Wilson, M.d, M.D
Urology — Payments: $4,258
Urology $4,258
Mariam Miller, M.d, M.D
Urology — Payments: $3,983
Urology $3,983
Zachary Posey, M.d, M.D
Urology — Payments: $2,310
Urology $2,310